Farallon Capital Management’s Veracyte VCYT Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$225K Hold
7,000
﹤0.01% 136
2025
Q4
$295K Hold
7,000
﹤0.01% 111
2025
Q3
$240K Buy
+7,000
New +$201K ﹤0.01% 114
2022
Q2
Sell
-32,500
Closed -$896K 326
2022
Q1
$896K Sell
32,500
-158,658
-83% -$4.54M ﹤0.01% 226
2021
Q4
$7.88M Buy
191,158
+5,936
+3% +$262K 0.04% 148
2021
Q3
$8.6M Buy
+185,222
New +$8.08M 0.04% 141
2020
Q3
Sell
-850,000
Closed -$22M 137
2020
Q2
$22M Sell
850,000
-525,000
-38% -$13.1M 0.18% 84
2020
Q1
$33.4M Buy
1,375,000
+375,000
+38% +$9.44M 0.29% 53
2019
Q4
$27.9M Hold
1,000,000
0.19% 75
2019
Q3
$24M Buy
1,000,000
+650,000
+186% +$17.3M 0.18% 68
2019
Q2
$9.98M Buy
+350,000
New +$8.74M 0.06% 86

Other funds holding VCYT

Farallon Capital Management's VCYT Position: Q1 2026 in Review

Farallon Capital Management held its Veracyte (VCYT) position steady in Q1 2026 at 7,000 shares worth $225K. The position accounts for ﹤0.01% of the portfolio, ranked #136.

Farallon Capital Management first reported a position in VCYT in Q2 2019 and has held it in 11 quarters since. The position peaked at $33.4M in Q1 2020. 334 funds tracked by Wall St. Rank hold VCYT as of Q1 2026.

  • Farallon Capital Management held 7,000 shares of Veracyte worth $225K as of Q1 2026.
  • Farallon Capital Management left its Veracyte share count unchanged in Q1 2026.
  • Veracyte made up ﹤0.01% of Farallon Capital Management's portfolio in Q1 2026, its #136 holding.
  • Farallon Capital Management first reported a position in Veracyte in Q2 2019 and has held it in 11 quarters since.
  • Farallon Capital Management's Veracyte position peaked at $33.4M in Q1 2020.
  • 334 funds tracked by Wall St. Rank held Veracyte as of Q1 2026.

Based on Farallon Capital Management's 13F filing for Q1 2026, filed 15 May 2026.